About this Journal Submit a Manuscript Table of Contents
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 495212, 7 pages
http://dx.doi.org/10.1155/2013/495212
Review Article

Site-Specific Immunosuppression in Vascularized Composite Allotransplantation: Prospects and Potential

1Department of Plastic and Reconstructive Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
2Disciplina de Cirurgia Plástica, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo 04024-900, Brazil
3Division of Plastic and Hand Surgery, University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland
4Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA 15261, USA
5Research Center for Translational Medicine, Shanghai East Hospital, Tongji University, Shanghai 200120, China
6Pittsburgh Reconstructive Transplantation Program, Department of Plastic Surgery, 3550 Terrace Street, Pittsburgh, PA 15261, USA

Received 2 July 2012; Accepted 18 January 2013

Academic Editor: Gerald Brandacher

Copyright © 2013 Jonas T. Schnider et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. P. A. Lee, M. J. Yaremchuk, Y. C. Pan, M. A. Randolph, C. M. Tan, and A. J. Weiland, “Relative antigenicity of components of a vascularized limb allograft,” Plastic and Reconstructive Surgery, vol. 87, no. 3, pp. 401–411, 1991. View at Scopus
  2. S. Schneeberger, S. Lucchina, M. Lanzetta et al., “Cytomegalovirus-related complications in human hand transplantation,” Transplantation, vol. 80, no. 4, pp. 441–447, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Lanzetta, P. Petruzzo, R. Margreiter et al., “The international registry on hand and composite tissue transplantation,” Transplantation, vol. 79, no. 9, pp. 1210–1214, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. W. C. Breidenbach, G. R. Tobin, V. S. Gorantla, R. N. Gonzalez, and D. K. Granger, “A position statement in support of hand transplantation,” Journal of Hand Surgery, vol. 27, no. 5, pp. 760–770, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. S. A. Gruber, M. V. Shirbacheh, J. W. Jones, J. H. Barker, and W. C. Breidenbach, “Local drug delivery to composite tissue allografts.,” Microsurgery, vol. 20, no. 8, pp. 407–411, 2000.
  6. V. S. Gorantla, G. Brandacher, S. Schneeberger, et al., “Favoring the risk-benefit balance for upper extremity transplantation—the Pittsburgh Protocol,” Hand Clinics, vol. 27, no. 4, pp. 511–520, 2011.
  7. M. G. Solari, K. M. Washington, J. M. Sacks, et al., “Daily topical tacrolimus therapy prevents skin rejection in a rodent hind limb allograft model,” Plastic and Reconstructive Surgery, vol. 123, no. 2, supplement, pp. 17S–25S, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. K. S. Black, D. K. Nguyen, C. M. Proctor, M. P. Patel, and C. W. Hewitt, “Site-specific suppression of cell-mediated immunity by cyclosporine,” Journal of Investigative Dermatology, vol. 94, no. 5, pp. 644–648, 1990.
  9. T. Luger and C. Paul, “Potential new indications of topical calcineurin inhibitors,” Dermatology, vol. 215, no. 1, pp. 45–54, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. C. U. Ang-Tiu, C. F. Meghrajani, and C. C. Maano, “Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials,” Expert Review of Clinical Pharmacology, vol. 5, no. 1, pp. 91–97, 2012.
  11. C. McCaughey, M. Machan, R. Bennett, J. J. Zone, and C. M. Hull, “Pimecrolimus 1% cream for oral erosive lichen planus: a 6-week randomized, double-blind, vehicle-controlled study with a 6-week open-label extension to assess efficacy and safety,” Journal of the European Academy of Dermatology and Venereology, vol. 25, no. 9, pp. 1061–1067, 2010.
  12. M. Lebwohl, A. K. Freeman, M. S. Chapman, S. R. Feldman, J. E. Hartle, and A. Henning, “Tacrolimus ointment is effective for facial and intertriginous psoriasis,” Journal of the American Academy of Dermatology, vol. 51, no. 5, pp. 723–730, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. V. S. Gorantla, J. H. Barker, J. W. Jones, K. Prabhune, C. Maldonado, and D. K. Granger, “Immunosuppressive agents in transplantation: mechanisms of action and current anti-rejection strategies,” Microsurgery, vol. 20, no. 8, pp. 420–429, 2000.
  14. T. Truchuelo, B. Díaz-Ley, L. Ríos, J. Alcántara, and P. Jaén, “Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response,” Dermatology Online Journal, vol. 18, no. 1, p. 15, 2012.
  15. A. D. Ormerod, S. A. A. Shah, P. Copeland, G. Omar, and A. Winfield, “Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial,” British Journal of Dermatology, vol. 152, no. 4, pp. 758–764, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Soria, S. Agbo-Godeau, A. Taïeb, and C. Francès, “Treatment of refractory oral erosive lichen planus with topical rapamycin: 7 Cases,” Dermatology, vol. 218, no. 1, pp. 22–25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. A. C. Allison and E. M. Eugui, “Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil,” Immunological Reviews, vol. 136, pp. 5–28, 1993. View at Scopus
  18. E. Bertelmann, M. De Ruijter, N. Gong, S. Knapp, and U. Pleyer, “Survival of corneal allografts following topical treatment with the immunomodulator mycophenolate mofetil,” Ophthalmologica, vol. 224, no. 1, pp. 38–41, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Shoji, T. Fukumura, M. Kudo, A. Yanagawa, J. Shimada, and Y. Mizushima, “Effect of topical preparation of mycophenolic acid on experimental allergic contact dermatitis of guinea-pigs induced by dinitrofluorobenzene,” Journal of Pharmacy and Pharmacology, vol. 46, no. 8, pp. 643–646, 1994. View at Scopus
  20. M. R. Prausnitz and R. Langer, “Transdermal drug delivery,” Nature Biotechnology, vol. 26, no. 11, pp. 1261–1268, 2008.
  21. A. C. Williams and B. W. Barry, “Penetration enhancers,” Advanced Drug Delivery Reviews, vol. 56, no. 5, pp. 603–618, 2004.
  22. Y. N. Kalia, A. Naik, J. Garrison, and R. H. Guy, “Iontophoretic drug delivery,” Advanced Drug Delivery Reviews, vol. 56, no. 5, pp. 619–658, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. M. R. Prausnitz, “Microneedles for transdermal drug delivery,” Advanced Drug Delivery Reviews, vol. 56, no. 5, pp. 581–587, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Hautz, B. Zelger, J. Grahammer et al., “Molecular markers and targeted therapy of skin rejection in composite tissue allotransplantation,” American Journal of Transplantation, vol. 10, no. 5, pp. 1200–1209, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. M. P. Schön, T. Krahn, M. Schön et al., “Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation,” Nature Medicine, vol. 8, no. 4, pp. 366–372, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. S. A. Gruber, “The case for local immunosuppression,” Transplantation, vol. 54, no. 1, pp. 1–11, 1992.
  27. S. A. Gruber, W. J. M. Hrushesky, R. J. Cipolle et al., “Local immunosuppression with reduced systemic toxicity in a canine renal allograft model,” Transplantation, vol. 48, no. 6, pp. 936–943, 1989. View at Scopus
  28. S. A. Gruber, R. J. Cipolle, D. M. Canafax et al., “An implantable pump for intrarenal infusion of immunosuppressants in a canine autotransplant model,” Pharmaceutical Research, vol. 5, no. 12, pp. 781–785, 1988. View at Scopus
  29. T. J. M. Ruers, W. A. Buurman, and J. F. M. Smits, “Local treatment of renal allografts, a promising way to reduce the dosage of immunosuppressive drugs. Comparison of various ways of administering prednisolone,” Transplantation, vol. 41, no. 2, pp. 156–161, 1986. View at Scopus
  30. K. Yano, Y. Fukuda, R. Sumimoto, K. Sumimoto, H. Ito, and K. Dohi, “Suppression of liver allograft rejection by administration of 15-deoxyspergualin. Comparison of administration via the hepatic artery, portal vein, or systemic circulation,” Transplant International, vol. 7, no. 3, pp. 149–156, 1994. View at Scopus
  31. S. M. Stepkowski, S. Goto, T. Ito et al., “Prolongation of heterotopic heart allograft survival by local delivery of continuous low-dose cyclosporine therapy,” Transplantation, vol. 47, no. 1, pp. 17–23, 1989. View at Scopus
  32. X. Wang, E. J. Alfrey, A. Posselt, L. Tafra, A. M. Alak, and D. C. Dafoe, “Intraportal delivery of immunosuppression to intrahepatic islet allograft recipients,” Transplant International, vol. 8, no. 4, pp. 268–272, 1995. View at Publisher · View at Google Scholar · View at Scopus
  33. A. T. Iacono, R. J. Keenan, S. R. Duncan et al., “Aerosolized cyclosporine in lung recipients with refractory chronic rejection,” American Journal of Respiratory and Critical Care Medicine, vol. 153, no. 4, pp. 1451–1455, 1996. View at Scopus
  34. A. T. Iacono, G. C. Smaldone, R. J. Keenan et al., “Dose-related reversal of acute lung rejection by aerosolized cyclosporine,” American Journal of Respiratory and Critical Care Medicine, vol. 155, no. 5, pp. 1690–1698, 1997. View at Scopus
  35. A. T. Iacono, B. A. Johnson, W. F. Grgurich et al., “A randomized trial of inhaled cyclosporine in lung-transplant recipients,” The New England Journal of Medicine, vol. 354, no. 2, pp. 141–150, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Deuse, F. Blankenberg, M. Haddad et al., “Mechanisms behind local immunosuppression using inhaled tacrolimus in preclinical models of lung transplantation,” American Journal of Respiratory Cell and Molecular Biology, vol. 43, no. 4, pp. 403–412, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Furtado, R. Perdigoto, F. Oliveira, et al., “Local immunosuppression in clinical small bowel transplantation (report of two cases),” TPS, vol. 32, no. 6, pp. 1206–1208, 2000.
  38. G. Swann, “The skin is the body's largest organ,” Journal of Visual Communication in Medicine, vol. 33, no. 4, pp. 148–149, 2010.
  39. J. M. Jensen and E. Proksch, “The skin's barrier,” Giornale Italiana di Dermatologia. Minerva Dermatologica, vol. 144, no. 6, pp. 689–700, 2009.
  40. J. D. Bos, “The skin as an organ of immunity,” Clinical & Experimental Immunology, vol. 107, pp. 3–5, 1997.
  41. L. C. Cendales, A. D. Kirk, J. M. Moresi, P. Ruiz, and D. E. Kleiner, “Composite tissue allotransplantation: classification of clinical acute skin rejection,” Transplantation, vol. 81, no. 3, pp. 418–422, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Kanitakis, D. Jullien, P. Petruzzo et al., “Clinicopathologic features of graft rejection of the first human hand allograft,” Transplantation, vol. 76, no. 4, pp. 688–693, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. D. W. Mathes, M. A. Randolph, M. G. Solari et al., “Split tolerance to a composite tissue allograft in a swine model,” Transplantation, vol. 75, no. 1, pp. 25–31, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Schneeberger, V. S. Gorantla, T. Hautz, B. Pulikkottil, R. Margreiter, and W. P. A. Lee, “Immunosuppression and rejection in human hand transplantation,” Transplantation Proceedings, vol. 41, no. 2, pp. 472–475, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Siemionow and C. Ozturk, “Face transplantation,” Journal of Craniofacial Surgery, vol. 23, no. 1, pp. 254–259, 2012.
  46. K. V. Ravindra, J. F. Buell, C. L. Kaufman et al., “Hand transplantation in the United States: experience with 3 patients,” Surgery, vol. 144, no. 4, pp. 638–644, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. E. Morelon, J. Kanitakis, and P. Petruzzo, “Immunological issues in clinical composite tissue allo,” Transplantation, Transplantation, vol. 93, no. 9, pp. 855–859, 2012.
  48. M. Siemionow and C. Ozturk, “An update on facial transplantation cases performed between 2005 and 2010,” Plastic and Reconstructive Surgery, vol. 128, no. 6, pp. 707e–720e, 2011.
  49. S. Reitamo, J. Rissanen, A. Remitz et al., “Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial,” Journal of Investigative Dermatology, vol. 111, no. 3, pp. 396–398, 1998. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Banchereau and R. M. Steinman, “Dendritic cells and the control of immunity,” Nature, vol. 392, no. 6673, pp. 245–252, 1998. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Wollenberg, S. Sharma, D. Von Bubnoff, E. Geiger, J. Haberstok, and T. Bieber, “Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis,” Journal of Allergy and Clinical Immunology, vol. 107, no. 3, pp. 519–525, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Panhans-Groß, N. Novak, S. Kraft, and T. Bieber, “Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506),” Journal of Allergy and Clinical Immunology, vol. 107, no. 2, pp. 345–352, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. W. Hoetzenecker, R. Ecker, T. Kopp, A. Stuetz, G. Stingl, and A. Elbe-Bürger, “Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis,” Journal of Allergy and Clinical Immunology, vol. 115, no. 6, pp. 1276–1283, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Caproni, D. Torchia, E. Schincaglia et al., “Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis,” British Journal of Dermatology, vol. 155, no. 4, pp. 722–728, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. M. V. Shirbacheh, X. Ren, J. W. Jones et al., “Pharmacokinetic advantage of intra-arterial cyclosporin A delivery to vascularly isolated rabbit forelimb. I. Model development,” Journal of Pharmacology and Experimental Therapeutics, vol. 289, no. 3, pp. 1185–1190, 1999. View at Scopus
  56. M. V. Shirbacheh, T. A. Harralson, J. W. Jones et al., “Pharmacokinetic advantage of intra-arterial cyclosporin A delivery to vascularly isolated rabbit forelimb. II. Dose dependence,” Journal of Pharmacology and Experimental Therapeutics, vol. 289, no. 3, pp. 1191–1195, 1999. View at Scopus
  57. M. V. Shirbacheh, J. W. Jones, T. A. Harralson et al., “Pharmacokinetics of intra-arterial delivery of tacrolimus to vascularly isolated rabbit forelimb,” Journal of Pharmacology and Experimental Therapeutics, vol. 289, no. 3, pp. 1196–1201, 1999. View at Scopus
  58. M. V. Shirbacheh, J. W. Jones, W. C. Breidenbach, S. McCabe, J. H. Barker, and S. A. Gruber, “The case for local immunosuppression in composite tissue allotransplantation,” Transplantation Proceedings, vol. 30, no. 6, pp. 2739–2742, 1998. View at Publisher · View at Google Scholar · View at Scopus